sta 5326 Search Results


hy 14644 u18666a medchemexpress  (MedChemExpress)
94
MedChemExpress hy 14644 u18666a medchemexpress
Hy 14644 U18666a Medchemexpress, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/hy 14644 u18666a medchemexpress/product/MedChemExpress
Average 94 stars, based on 1 article reviews
hy 14644 u18666a medchemexpress - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier
apilimod mesylate  (MedChemExpress)
93
MedChemExpress apilimod mesylate
Antitumor assays in vitro . (A) Cell viability of RM-1 cells after treatment with LNP@PTEN and <t>Apilimod</t> + LNP@PTEN for 24 h ( n = 3, means ± SD). ns: no significance, 2way ANOVA. (B, C) The statistical analysis of cells in nine fields of view of (B) anti-migration effects and (C) anti-invasion effects, respectively ( n = 9, mean ± SD), * p < 0.05, ** p < 0.01, *** p < 0.001, ns: no significance, one-way ANOVA. (D) Microscope images of anti-migration effects and anti-invasion effects in each group (Apilimod: 10 nM, PTEN: 0.5 μg/mL), scale bars = 50 μm. (E) 3D tumor spheroid model. DiO-stained RM-1 cells and DiD-stained MC3T3-E1 cells. Blue fluorescence: DAPI, green fluorescence: DiO, red fluorescence: DiD, Scale bars = 100 μm. (F) The images of in vitro tumor spheroids penetration of each group were acquired by CLSM. DiO-stained LNPs (DiO: 20 μg/mL, Cy7-DNA: 0.5 μg/mL). Scale bars = 100 μm.
Apilimod Mesylate, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/apilimod mesylate/product/MedChemExpress
Average 93 stars, based on 1 article reviews
apilimod mesylate - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
sta 5326  (Synta Inc)
90
Synta Inc sta 5326
Antitumor assays in vitro . (A) Cell viability of RM-1 cells after treatment with LNP@PTEN and <t>Apilimod</t> + LNP@PTEN for 24 h ( n = 3, means ± SD). ns: no significance, 2way ANOVA. (B, C) The statistical analysis of cells in nine fields of view of (B) anti-migration effects and (C) anti-invasion effects, respectively ( n = 9, mean ± SD), * p < 0.05, ** p < 0.01, *** p < 0.001, ns: no significance, one-way ANOVA. (D) Microscope images of anti-migration effects and anti-invasion effects in each group (Apilimod: 10 nM, PTEN: 0.5 μg/mL), scale bars = 50 μm. (E) 3D tumor spheroid model. DiO-stained RM-1 cells and DiD-stained MC3T3-E1 cells. Blue fluorescence: DAPI, green fluorescence: DiO, red fluorescence: DiD, Scale bars = 100 μm. (F) The images of in vitro tumor spheroids penetration of each group were acquired by CLSM. DiO-stained LNPs (DiO: 20 μg/mL, Cy7-DNA: 0.5 μg/mL). Scale bars = 100 μm.
Sta 5326, supplied by Synta Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sta 5326/product/Synta Inc
Average 90 stars, based on 1 article reviews
sta 5326 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
apilimod (sta-5326)  (Aladdin Scientific Corporation)
N/A
InformationApilimod (STA-5326) Apilimod (STA-5326) is a potent and orally-available inhibitor of the cytokines interleukin-12 (IL-12) and interleukin-23 (IL-23) with the potential to treat certain autoimmune and inflammatory diseases. Apilimod (STA-5326) inhibitsIn vitroApilimod selectively inhibits TLR-induced
   Buy from Supplier

Image Search Results


Antitumor assays in vitro . (A) Cell viability of RM-1 cells after treatment with LNP@PTEN and Apilimod + LNP@PTEN for 24 h ( n = 3, means ± SD). ns: no significance, 2way ANOVA. (B, C) The statistical analysis of cells in nine fields of view of (B) anti-migration effects and (C) anti-invasion effects, respectively ( n = 9, mean ± SD), * p < 0.05, ** p < 0.01, *** p < 0.001, ns: no significance, one-way ANOVA. (D) Microscope images of anti-migration effects and anti-invasion effects in each group (Apilimod: 10 nM, PTEN: 0.5 μg/mL), scale bars = 50 μm. (E) 3D tumor spheroid model. DiO-stained RM-1 cells and DiD-stained MC3T3-E1 cells. Blue fluorescence: DAPI, green fluorescence: DiO, red fluorescence: DiD, Scale bars = 100 μm. (F) The images of in vitro tumor spheroids penetration of each group were acquired by CLSM. DiO-stained LNPs (DiO: 20 μg/mL, Cy7-DNA: 0.5 μg/mL). Scale bars = 100 μm.

Journal: Frontiers in Pharmacology

Article Title: IL-23 inhibitor enhances the effects of PTEN DNA-loaded lipid nanoparticles for metastatic CRPC therapy

doi: 10.3389/fphar.2024.1388613

Figure Lengend Snippet: Antitumor assays in vitro . (A) Cell viability of RM-1 cells after treatment with LNP@PTEN and Apilimod + LNP@PTEN for 24 h ( n = 3, means ± SD). ns: no significance, 2way ANOVA. (B, C) The statistical analysis of cells in nine fields of view of (B) anti-migration effects and (C) anti-invasion effects, respectively ( n = 9, mean ± SD), * p < 0.05, ** p < 0.01, *** p < 0.001, ns: no significance, one-way ANOVA. (D) Microscope images of anti-migration effects and anti-invasion effects in each group (Apilimod: 10 nM, PTEN: 0.5 μg/mL), scale bars = 50 μm. (E) 3D tumor spheroid model. DiO-stained RM-1 cells and DiD-stained MC3T3-E1 cells. Blue fluorescence: DAPI, green fluorescence: DiO, red fluorescence: DiD, Scale bars = 100 μm. (F) The images of in vitro tumor spheroids penetration of each group were acquired by CLSM. DiO-stained LNPs (DiO: 20 μg/mL, Cy7-DNA: 0.5 μg/mL). Scale bars = 100 μm.

Article Snippet: Apilimod mesylate was purchased from MedChemExpress (United States).

Techniques: In Vitro, Migration, Microscopy, Staining, Fluorescence

In vivo study of LNPs. (A) Representative images of BmCRPC-bearing mice from each group were taken at 0–24 h after injection, with the tumor area marked by a red circle. (B) Fluorescence imaging of tumors and major organs. (C) The semiquantitative fluorescence intensity in major organs of each group ( n = 3, mean ± SD), * p < 0.05, ** p < 0.01, *** p < 0.001, multiple t -test. (D) The in vivo study protocol of Apilimod + LNP@PTEN (PTEN DNA: 700 μg/kg, Apilimod: 10 mg/kg). (E) The five groups’ tumor volume curves ( n = 5, mean ± SD). (F) The five groups’ weight curves ( n = 5, mean ± SD). (G) Mice growth curves for body weight among the five groups ( n = 5, mean ± SD). (H) RT-qPCR results of the expression of PTEN in different treatment groups (n = 3, mean ± SD), *** p < 0.001, **** p < 0.0001, one-way ANOVA. (I) Survival curve of mice in different treatment groups ( n = 5, mean ± SD). **** p < 0.0001, ns: no significance, one-way ANOVA.

Journal: Frontiers in Pharmacology

Article Title: IL-23 inhibitor enhances the effects of PTEN DNA-loaded lipid nanoparticles for metastatic CRPC therapy

doi: 10.3389/fphar.2024.1388613

Figure Lengend Snippet: In vivo study of LNPs. (A) Representative images of BmCRPC-bearing mice from each group were taken at 0–24 h after injection, with the tumor area marked by a red circle. (B) Fluorescence imaging of tumors and major organs. (C) The semiquantitative fluorescence intensity in major organs of each group ( n = 3, mean ± SD), * p < 0.05, ** p < 0.01, *** p < 0.001, multiple t -test. (D) The in vivo study protocol of Apilimod + LNP@PTEN (PTEN DNA: 700 μg/kg, Apilimod: 10 mg/kg). (E) The five groups’ tumor volume curves ( n = 5, mean ± SD). (F) The five groups’ weight curves ( n = 5, mean ± SD). (G) Mice growth curves for body weight among the five groups ( n = 5, mean ± SD). (H) RT-qPCR results of the expression of PTEN in different treatment groups (n = 3, mean ± SD), *** p < 0.001, **** p < 0.0001, one-way ANOVA. (I) Survival curve of mice in different treatment groups ( n = 5, mean ± SD). **** p < 0.0001, ns: no significance, one-way ANOVA.

Article Snippet: Apilimod mesylate was purchased from MedChemExpress (United States).

Techniques: In Vivo, Injection, Fluorescence, Imaging, Quantitative RT-PCR, Expressing